Predictors of response to rituximab in patients with neuropathy and anti?myelin associated glycoprotein immunoglobulin M
| Autor: | Marina Grandis, Maria Pia Sormani, Marinella Carpo, Marco Gobbi, Luana Benedetti, Angelo Schenone, Chiara Briani, Christina M. Caporale, Elisabetta Ghiglione, Eduardo Nobile-Orazio, Tiziana Vigo, Dario Cocito, Giovanni Luigi Mancardi |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Antigens CD19 Blotting Western B-Lymphocyte Subsets Neural Conduction Antibodies Monoclonal Murine-Derived Polyneuropathies Antigen medicine Humans Immunologic Factors Muscle Strength Aged Autoantibodies B-Lymphocytes Myelin-associated glycoprotein biology Electromyography business.industry General Neuroscience Antibody titer Antibodies Monoclonal Middle Aged Flow Cytometry medicine.disease Myelin-Associated Glycoprotein Immunoglobulin M nervous system Monoclonal Immunology biology.protein Female Rituximab Neurology (clinical) Antibody business Polyneuropathy medicine.drug |
| Zdroj: | Journal of the Peripheral Nervous System. 12:102-107 |
| ISSN: | 1529-8027 1085-9489 |
| DOI: | 10.1111/j.1529-8027.2007.00129.x |
| Popis: | We evaluated the efficacy and safety of rituximab in an open-label, uncontrolled study of 13 patients with polyneuropathy associated with antibodies to myelin-associated glycoprotein (MAG) and correlated the response to therapy with clinical and laboratory features. One year after rituximab therapy, anti-MAG immunoglobulin M (IgM) titers were significantly reduced. At that time, eight patients (62%) had improved in both the inflammatory neuropathy cause and treatment (INCAT) sensory sumscore and the Medical Research Council sumscore for muscle strength and seven of them also in the INCAT disability score. The improvement in the mean INCAT sensory sumscore was significant at 12 months and correlated with lower anti-MAG antibody at entry and at follow-up. This study suggests that rituximab may be efficacious in patients with anti-MAG associated neuropathy and particularly on sensory impairment and in those with moderately elevated antibody titers. These findings suggest that antibody reduction below a critical level may be necessary to achieve clinical improvement. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|